Together, Aβ and Neurodegeneration Spell Cognitive Decline in Three Years
Data suggest Aβ-dependent and –independent pathways combine forces to compromise cognition in otherwise healthy people.
587 RESULTS
Sort By:
Data suggest Aβ-dependent and –independent pathways combine forces to compromise cognition in otherwise healthy people.
Introducing a clinical trials database for ALS that encompasses nearly 9,000 patient records, the organizers tease with the first few findings.
By beaming red light at a blood sample and measuring the scattered photons, scientists claim to identify people with Alzheimer’s disease.
A sense of change on all fronts pervaded the Clinical Trials on Alzheimer’s Disease conference. Scientists shared their early experiences of what works and what does not as they begin trials with newly defined cohorts, new diagnostic criteria, and new outcomes.
Researchers at CTAD advanced tau research on several fronts, correlating tau PET with Braak stage and memory loss, and introducing a new tau model and therapeutic antibody.
Scientists claim that MRI detects an Aβ oligomer-specific probe delivered to the mouse brain through the nose.
Measuring total prion protein in cerebrospinal fluid could help clinicians differentiate between prion disease and rapidly progressing forms of dementia.
Cross-sectional biomarker data from the Colombian kindred confirm models of biomarker progression, but suggest an earlier drop in brain metabolism.
All three PET agents demonstrate roughly equivalent abilities to detect brain amyloid, a new analysis finds.
Spinal taps have a bad rap. Are headaches really all that common afterwards, and are there ways to prevent them?
For the first time, scientists report a crystal structure of TSPO, a potential target for PET imaging of neuroinflammation.
Early data suggest that the T807/AV1451 signal relates to cerebrospinal biomarkers of Alzheimer’s, intensifies by up to 10 percent a year, and might nail diagnoses beyond typical AD.
Cognitively normal people with levels of CSF Aβ42 near the cutoff point associated with amyloid pathology are likely to cross that threshold within three years.
Two new open-access journals will cover specialized areas of Alzheimer’s research.
Qualification could follow, but only if trial sponsors fork over fresh data.